Skip to content

Study to verify the effectiveness of SYS-055 administration in reducing fatigue

Study to verify the effectiveness of SYS-055 administration in reducing fatigue

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031220483
Enrollment
15
Registered
2022-12-02
Start date
2022-12-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Take one bottle once a day after breakfast.

Sponsors

Tsuyoshi Takara
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Japanese male or female, 18 years of age or older 3. Subjects who are judged by the principal investigator to be safe to participate in the study based on the BDI-II results at the screening test

Exclusion criteria

Exclusion criteria: 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects whose lifestyles are irregular (whose habits vary every day such as dietary habits, exercise habits, and sleeping habits) 5. Subjects who do not take 3 meals a day including breakfast 6. Subjects who have physical labor such as transportation of heavy objects 7. Subjects who are currently taking medications (including herbal medicines) and supplements 8. Subjects who habitually take excessive amounts of soft drinks containing caffeine (such as energy drinks) 9. Subjects who regularly take foods or medicines containing ingredients that may affect fatigue or stress 10. Subjects who are allergic to medications and/or the test-food-related products (particularly alcohol) 11. Subjects who are pregnant, lactating, or planning to become pregnant during this trial 12. Subjects who suffer from COVID-19 13. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 14. Subjects who are judged as ineligible to participate in this study by the physician

Design outcomes

Primary

MeasureTime frame
Subjective symptom: Visual analogue scale of fatigue

Secondary

MeasureTime frame
1. Subjective symptoms: POMS2, Chalder's Fatigue Scale 2. Stress: blood cortisol, salivary cortisol, salivary amylase 3. Oxidative stress: blood d-ROMs, blood BAP, BAP/d-ROMs, urinary 8-OHdG 4. Immune function: NK cell activity 5. Autonomic nervous system function 6. Physical function: Physical Work Capacity test using ergometer 7. Psychological testing: Uchida-Kraepelin test

Contacts

Public ContactSuzuki Naoko

ORTHOMEDICO Inc.

group_gakujutsu@orthomedico.jp+81-3-3813-5106

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026